SGRY Surgery Partners, Inc.
Services-General Medical & Surgical Hospitals, NEC · Nasdaq · SEC CIK 1638833 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY2.2%
TTM net income YoY49.2%
TTM EPS YoY50.7%
Revenue 3-yr CAGR7.4%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin10.8%
Net margin-2.6%
FCF margin6.0%
EBITDA margin16.1%
Returns
ROE-5.1%
ROA-1.2%
ROIC (approx.)6.1%
Asset turnover0.45x
Leverage & solvency
Liabilities / assets53.8%
Debt / equity1.84x
Current ratio2.17x
Interest coverage—
Cash quality & payout
Operating cash flow / net income-3.19x
Accruals ratio-4.9%
Payout ratio—
Capex / revenue2.2%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $3.31B | $3.11B |
| SG&A expense | $118.20M | $138.70M |
| Operating income | $389.50M | $348.80M |
| Pretax income | $116.90M | $147.10M |
| Income tax | $18.00M | $134.60M |
| Net income | -$77.90M | -$168.10M |
| EBITDA | $565.50M | $501.40M |
| EPS (basic) | -0.61 | -1.33 |
| EPS (diluted) | -0.61 | -1.33 |
| Weighted avg. shares (diluted) | 127.21M | 126.12M |
| Balance sheet | ||
| Cash & equivalents | $239.90M | $269.50M |
| Receivables | $602.20M | $579.10M |
| Inventory | $96.60M | $88.40M |
| Current assets | $1.15B | $1.12B |
| PP&E, net | $1.15B | $1.09B |
| Goodwill | $5.19B | $5.07B |
| Intangibles | $41.00M | $45.70M |
| Total assets | $8.12B | $7.89B |
| Current liabilities | $615.50M | $624.40M |
| Short-term debt | $99.30M | $101.40M |
| Long-term debt | $3.60B | $3.27B |
| Total debt | $3.70B | $3.37B |
| Total liabilities | $4.59B | $4.25B |
| Shareholders' equity | $1.71B | $1.79B |
| Net debt | $3.46B | $3.10B |
| Shares outstanding | 129.32M | 127.11M |
| Cash flow statement | ||
| Operating cash flow | $274.30M | $300.10M |
| Capital expenditure | $78.70M | $90.40M |
| Free cash flow | $195.60M | $209.70M |
| Investing cash flow | -$246.60M | -$488.50M |
| Financing cash flow | -$57.30M | $262.00M |
| Depreciation & amortization | $176.00M | $152.60M |
| Stock-based compensation | $14.80M | $33.30M |
Free plan shows the latest 2 periods; Pro shows all 12 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.